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Age, malignancy, and cell dose had no impact on OI. The median
values for major leukocytes were; WBC: 0.7  10e3/l, T cells:
63/l, NK cells: 47/l, B cells: 0/l, CD4T cells: 42/l,
%CD4 T cells: 66%. Both the OI and OI group had com-
parable WBC, CD3, CD4 T cells, NK lymphocytes, or DC1,
DC2 subsets. Strikingly, 44% of circulating T cells were in cell
cycle (KI-67) and 10% were entering apoptosis (activated
Caspase-3), regardless of OI status. Only 16% preserved the
CD45RA/CD62L phenotype of the infused graft. We con-
clude that in lymphopenic UCBT recipients even undetectable
viral infections may induce T cell maturation towards effector
CD8 Tc1 cells as soon as 2–3 weeks after UCBT allowing early
identiﬁcation of those at risk for clinical OI (Table1).
Differences in Lymphocyte Reconstitution Between Those Who Will
Develop Opportunisitic Infections (OI) or Not
Variable
OI Median
Value
OI Median
Value P-Value
% CD8 T cells 39 28 .04
% CCR-5 T cells 85 56 .005
% CD8/CD57/CD28 6 2.8 .027
Abs
CD8/CD57/CD28 1.3 0.4 .017
% IFN T cells 35.1 12.2 .006
% CD4/IFN T cells 14 10 .017
% CD8/Perforin T cells 48 26 .019
MFI of BCL-2 in T cells 76 54 .036
Absolute values in microliter.
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FACTORS AFFECTING IMMUNOLOGIC RECOVERY AFTER NONMYELOA-
BLATIVE CONDITIONING
Baron, F.1, Piette, F.1, Maris, M.1, Storek, J.1, Metcalf, M.1,
White, K.1, Sandmaier, B.1, Maloney, D.1, Storer, B.1, Storb, R.1,
Boeckh, M.1 Fred Hutchinson Cancer Research Center, Seattle, WA.
Background/Methods: We investigated factors affecting im-
mune recovery after nonmyeloablative (NM) conditioning in 94
pts given PBSC from HLA-matched related (MRD, n  51) or
unrelated (URD, n  43) donors after 2 Gy TBI / ﬂudarabine.
Postgrafting immunosuppression (IS) consisted of mycophenolate
mofetil (MMF, given TID for 40 days followed by a 56 day taper
in URD recipients, and BID for 28 days in MRD recipients) and
cyclosporin. Univariate and multivariate analyses were performed
to determine factors affecting counts of CD4 T cells, naive CD4 T
cells, CD8 T cells, B cells, and frequency of CMV-speciﬁc CD4
T-helper cells (among CMV seropositive pts or CMV-seronega-
tive pts with CMV-seropositive donors; determined by lympho-
proliferation (CMV-CPM)) on days 30, 80, 180, and 365 after
HCT.Results: In multivariate analyses, URD recipients had lower
counts of CD4 T cells, naive CD4 T cells, CD8 T cells, and
CMV-CPM than MRD on day 30 after HCT. This delay in
CMV-speciﬁc immune reconstitution was accompanied by in-
creased frequency of CMV-reactivation (and increased use of pre-
emptive antiviral therapy [PET]) among CMV-seropositive pts or
CMV-seronegative pts with CMV sero-positive donors given
URD grafts (cumulative incidence [CI] 61%) compared with MRD
(33%) recipients the ﬁrst 100 days after HCT. This did not lead to
increased CMV disease among URD recipients (1 episode) com-
pared with MRD recipients (1 episode), demonstrating that PET
was similarly effective in preventing CMV diseases in both groups.
Higher donor age was associated with lower counts of naive CD4
T cells, suggesting that most naive CD4 T cells derived from
transplanted naive CD4 T cells rather than through neo-genera-
tion. As seen in pts given myeloablative conditioning, CMV-sero-
positive patients had higher levels of CD8 T cells after HCT.
Further, lower levels of T cells and CD34 cells in the grafts, as
well as acute GVHD, impaired immune recovery of naive CD4 T
cells and B-cells (Table 1). Conclusions: Despite similar NM
conditioning regimens, immunologic recovery was delayed among
URD recipients in comparison to MRD recipients, either because
of increased/extended postgrafting IS or the greater degrees of
antigenic disparities between donors and recipients. This resulted
in a higher incidence of CMV-infection and increased use of PET.
Other factors associated with immune recovery were donor age,
patient CMV-serostatus, number of CD34 and T cells in the graft,
as well as acute GVHD (Table 1).
Table 1. Multivariate Analyses of Factors Affecting Immune
Recovery After NM Conditioning
Cell Subset
Day
After HCT
Factor(s) Associated With
Lower Cell Subset Counts
CD4 T-cell 30 URD vs MRD (P  .06)
CD4 T-cell 80 URD vs MRD (P  .003);
High donor age
(P  .006)
CD4 T-cell 180 & 365 MRD vs URD (P  .035)
Naive CD4 T-cell 30 URD vs MRD (P < .001);
High donor age
(P  .001)
Naive CD4 T-cell 80 Low # of CD34 cells
transplanted (P  .006);
Grade II–IV acute
GVHD (P  .007)
Naive CD4 T-cell 180 & 365 High donor age
(P  .003); Pt CMV
seropositive (P  .03)
CD8 T-cell 30 URD vs MRD (P < .001)
CD8 T-cell 80 Pt CMV seronegative
(P  .018)
CD8 T-cell 180 & 365 Pt CMV seronegative
(P  .06)
B-cell 30 Low no. of CD34 cells
transplanted
(P  .022); Low # of
T-cells transplanted
(P  .039)
B-cell 80 Low no. of T-cells
transplanted
(P  .002); Grade II–IV
acute GVHD (P  .08)
B-cell 180 & 365 Grade II–IV acute GVHD
(P  .031)
CMV-
CPM† 30 URD vs MRD (P  .007)
CMV-
CPM† 80 URD vs MRD (P  .008);
Low no. of T-cells
transplanted (P  .02)
CMV-
CPM† 180 & 365 Low no. of T-cells
transplanted (P  .01)
Other factors assessed were pt age, prior chemotherapy or not,
day 28 T-cell chimerism, extensive chronic GVHD; contin-
uous linear variable; †analyses restricted to CMV seropositive
pt or donor.
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SIGNIFICANCE OF LYMPHOCYTE CONTRIBUTION POST PROCESSING IN
CORD BLOOD TRANSPLANTATION
Wofford, J.D.1, Regan, D.M.1, Alonso, J.M.F.1, Creer, M.H.2 1. St.
Louis Cord Blood Bank at SSM Cardinal Glennon Children’s Hospital,
St. Louis, MO; 2. St. Louis University, St. Louis, MO.
In cord blood transplantation, engrafting cell populations include
hematopoietic stem/progenitor cells. Naive and antigen-speciﬁc T
and B cells mediate protective immune responses as well as graft-
versus-host reactions. Total Nucleated Cell Dose (TNC) has con-
sistently been shown to correlate with recipient outcome. A major
complication, including death, in post transplant recovery is infec-
tion. In this preliminary analysis, we attempt to determine the
signiﬁcance of the lymphocyte contribution with regard to infec-
tion control post cord blood infusion. The outcomes of 318 single
cord blood unit transplants have been evaluated. Recipients were
assigned to groups based on the percentage of lymphocytes post
processing. The overall mean was 30%. Group 1 consists of recip-
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ients with a lymphocyte percentage  30% (n  153), and group
2 consists of recipients with a lymphocyte percentage 	30%
(n  165). As this is a preliminary analysis, the population has not
been limited by disease, disease status, and other potential factors
inﬂuencing outcome. Total Nucleated Cell Dose (P  .77), HLA
Matching (P  .14), and Recipient Age (P  .03), have been
evaluated to eliminate bias between the two groups. The purpose
of this analysis is to determine if a relationship exists between
lymphocyte percentage and the incidence of infection and cause of
death by infection. There was not a signiﬁcant difference in the
incidence of infection (bacterial, viral, fungal) post transplant be-
tween the two groups. Group 1 had an incidence of 131 (86%)
patients with infection, and Group 2 had an incidence of 134 (81%)
(P  .36). There was however, an extremely signiﬁcant difference
in the number of patients with a primary cause of death by infec-
tion. Group 1 experienced 73 deaths with 31 (43%) by infection,
while Group 2 experienced 75 deaths with 10 (13%) by infection
(P  .0001). With median TNC dose/kg being nearly equal be-
tween the two groups (4.0;4.5 P  .77), this preliminary analysis
indicates that there may be characteristics within the nucleated cell
populations that are critical to transplant outcome.
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ASSESSING IMMUNE FUNCTION IN ALLOGENEIC AND AUTOLOGOUS
BONE MARROW TRANSPLANT RECIPIENTS USING THE Cylex Immu-
Know ASSAY
Post, D.R.1, Martin, M.C.1, Kowalski, R.J.1 Cylex Incorporated, Co-
lumbia, MD.
The Cylex Immune Cell Function Assay (ImmuKnow) is cleared
by the FDA for the detection of cell-mediated immunity in an
immunosuppressed population. The assay measures the immune
function of CD4 T-helper cells from a small sample of whole
blood by stimulating the sample with phytohemagglutinin, selec-
tion of CD4 cells with antibody coated magnetic particles, and
detection of ATP by bioluminescence. CD4 T-helper cells that
respond to stimulating increase their production of ATP that
provide an objective measure of immune responsiveness. This test
has demonstrated clinical utility for managing immunosuppressive
therapies in solid-organ transplantation (SOT). Outcome data
from SOT recipients have identiﬁed risk zones for infection or
allograft rejection based on immune function values determined by
the ImmuKnow assay. Observational studies conducted at several
cancer centers and Universities in the United States involving over
200 patients have shown that this test provides an independent
measurement of engraftment, immune reconstitution, and immune
function in allogeneic and autologous bone marrow transplant
recipients. By assessing immune function in BMT recipients it is
possible to avoid infectious complications, manage immunosup-
pressive therapy, and scheduling of chemotherapy.
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BUSULFAN AND MELPHALAN AS PREPARATIVE THERAPY FOR STEM
CELL TRANSPLANTATION IN PEDIATRIC PATIENTS WITH ACUTE MY-
ELOGENOUS LEUKEMIA (AML) AND MYELODYSPLASIA (MDS)
Andreansky, M.1, Fiederlein, R.1, Graham, M.L.1 The University of
Arizona, Tucson, AZ.
Fifty-two pediatric patients (ages 10 months to 23 years) with
primary AML (n  39), secondary AML (n  5), and MDS (n 
8) received busulfan (600 mg/m2) and melphalan (140–180 mg/m2)
with equine antithymocyte globulin (60 mg/kg) for unrelated do-
nor stem cell recipients as preparative therapy for stem cell trans-
plant. Stem cell sources consisted of allogeneic marrow (sibling
n  16, parent n  2), unrelated marrow (n  3), unrelated cord
blood (n  30), and syngeneic marrow (n  1). Regimen-related
toxicities included grade 3 or 4 mucositis (n  52) and venoocclu-
sive disease (n  3). All patients surviving 30 days demonstrated
myeloid engraftment. One hundred day survival was 77% (40/52);
100% for matched family and syngeneic donor and 64% (21/33)
for unrelated donor recipients. Causes of deaths within 100 days
were: infection / GVHD (n  6), multiorgan failure (n  2),
CNS hemorrhage (n  2), alveolar proteinosis (n  1), and trans-
fusion reaction (n 1). Of 18 patients transplanted from allogeneic
family donors, 15 survived event-free a median of 84months post
transplant; 2 of the 3 who relapsed underwent second transplants
and survived event-free 108 and 13months. Of 33 patients who
underwent unrelated donor transplants, 16 survived event-free a
median of 46 months post transplant. Four of the 33 patients
relapsed and a total of 13 died of transplant-related complications.
Of the 33 patients who received unrelated donor transplants, 9 of
15 with AML in CR1 or CR2 survived event-free a median of 60
months, 3 of 10 in relapse survived event-free 114, 107, and 8
months, and 4 of 8 with MDS survived event-free 35, 35, 23,
and 5 months. The combination of busulfan and melphalan is an
effective preparative regimen for pediatric patients with acute my-
elogenous leukemia and myelodysplasia and, in combination with
equine antithymocyte globulin, provides adequate immunosup-
pression for unrelated donor transplants.
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IMPACT OF TIMING OF ALLOGENEIC STEM CELL TRANSPLANTATION IN
CML PATIENTS IN THE IMATINIB ERA
Schleuning, M.1, Judith, D.1, Burlakova, I.1, Baurmann, H.1,
Schwerdtfeger, R.1 Center for Hematopoietic Cell Transplantation,
Deutsche Klinik fuer Diagnostik, Wiesbaden, Germany.
Imatinib mesylate (IM), a small molecule targeting the BCR-
ABL kinase, is now considered to be the standard ﬁrst line treat-
ment of chronic myeloid leukemia (CML). Although IM induces a
high rate of cytogenetic remissions and may prolong progression-
free survival in CML patients (pts), complete molecular remissions
remain a rare event. Therefore, it remains questionable whether
IM represents a curative treatment. By contrast, the curative po-
tential of allogeneic stem cell transplantation (SCT) has been
proven. However, because of its treatment-related mortality
(TRM) nowadays SCT often is being offered to pts only after
failure of IM and thereby also delayed beyond one year after
diagnosis. The best timing for SCT for CML pts on IM remains to
be deﬁned. Therefore, we retrospectively analyzed the outcome of
all pts transplanted at our center who had received IM prior to
SCT. From the 27 consecutive CML pts included in this analysis,
11 had proven to be resistant to IM therapy. Resistance was deﬁned
by primary cytogenetic unresponsiveness or increasing percentage
of Ph metaphases or hematological progression. Fifteen pts were
transplanted in ﬁrst chronic phase and 12 in advanced disease (CP2
n  10; BC n  2). There were no signiﬁcant differences with
respect to age, donor (sibling vs unrelated), and stage of disease by
means of -square tests between the IM resistant and responding
groups. However, signiﬁcantly more pts were transplanted within
the ﬁrst year after diagnosis in the IM responding group. No
differences could be observed concerning the incidences of acute
GvHD grades II–IV, or extensive chronic GvHD between the two
groups. IM resistance was associated with a higher TRM at 100
days (36 vs 0%, P  .008) and an inferior projected overall survival
at 2 years (39 vs 70%, P .028). The poorer outcome of the IM
resistant group may be due to a longer time interval between
diagnosis and transplantation or to a transformation of the CML
clone into a more resistant leukemia requiring more aggressive
chemotherapy prior to transplantation and thus increasing the risk
of TRM. In summary, these data provide some evidence that either
IM resistance may be an adverse prognostic factor for CML pts
undergoing allogeneic SCT or that the better prognosis for pts
transplanted early during the disease also holds true in the IM era.
However, larger patient numbers and prospective trials are man-
datory to deﬁne the best timing for SCT for CML pts on IM
therapy.
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